Retatrutide

Weight Loss

30Vendors

The heavyweight of experimental weight-loss peptides. People chase it for powerful appetite suppression and dramatic body-fat reduction, and trial data support unusually large losses for an obesity drug.

View Vendors

Studies
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.	PubMed
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.	PubMed
Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression.	PubMed

Retatrutide Vendors
Mile High Compounds 5.0	Profile
Alpha Peptides 0.0	Profile
Ameano Peptides 0.0	Profile
Ascension Peptides 0.0	Profile
BioCollex 0.0	Profile
Coastal Peptides 0.0	Profile
Eternal Peptides 0.0	Profile
Evolve BioPep 0.0	Profile
EZ Peptides 0.0	Profile
Flawless Compounds 0.0	Profile
Genpeptide 0.0	Profile
Glacier Aminos 0.0	Profile
Glow Aminos 0.0	Profile
Instant Peptides 0.0	Profile
Ion Peptides 0.0	Profile
LA Peptides 0.0	Profile
Midwest Peptide 0.0	Profile
Modern Aminos 0.0	Profile
NextGenPeps 0.0	Profile
Nura Peptide 0.0	Profile
Orbitrex Peptides 0.0	Profile
Penguin Peptides 0.0	Profile
Peptidology 0.0	Profile
Peptira 0.0	Profile
Pepvida Labs 0.0	Profile
Prime Peptides 0.0	Profile
Puratek Peptides 0.0	Profile
S1Research 0.0	Profile
Southern Aminos 0.0	Profile
Tydes 0.0	Profile

Retatrutide Vendors